IDEXX Laboratories, Inc. vs PepsiCo, Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while PepsiCo, Inc. trades at $138.55 (market cap $188.91B). The key difference: PepsiCo, Inc. is far larger — about 4.1× IDEXX Laboratories, Inc.'s market cap, and PepsiCo, Inc. pays a 4.28% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | PEP | |
|---|---|---|
Market Cap | $46.22B | $188.91B |
Sector | Health | Consumer Staples |
52-Week High | $766.68 | $170.44 |
52-Week Low | $526.44 | $134.95 |
Enterprise Value | $47.12B | $231.41B |
Dividend Yield | — | 4.28% |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
PepsiCo (PEP) trades at $138.22, up 0.38% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $2.20 beating expectations of $2.19, and robust profitability metrics including 10.78% net income margin and 51.59% ROE. Recent news highlights price adjustments for snacks and sponsorship changes, while analysts maintain a cautious but generally positive outlook.
PepsiCo presents a stable investment case with strong cash flow generation and dividend consistency, though near-term headwinds include pricing sensitivity and competitive pressures. The consensus price target of $158.79 suggests 15% upside potential, supported by ongoing business optimization efforts. Key risks include consumer pushback on pricing and execution challenges in North American markets.
Trailing returns across standard periods
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →